Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics
Introduction: Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotec...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024923011683 |
| _version_ | 1797833603379363840 |
|---|---|
| author | Raphael Weiss Melanie Meersch Carola Wempe Thilo von Groote Tobias Agervald Alexander Zarbock |
| author_facet | Raphael Weiss Melanie Meersch Carola Wempe Thilo von Groote Tobias Agervald Alexander Zarbock |
| author_sort | Raphael Weiss |
| collection | DOAJ |
| description | Introduction: Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotective effects. RMC-035, a recombinant variant of endogenous human A1M, is being developed for the prevention of AKI in cardiac surgery patients. Methods: In this phase 1b, randomized, double-blind, and parallel group clinical study, 12 cardiac surgery patients undergoing elective, open-chest, on-pump coronary artery bypass graft and/or valve surgery with additional predisposing AKI risk factors were enrolled to receive in total 5 intravenous doses of either RMC-035 or placebo. The primary objective was to evaluate the safety and tolerability of RMC-035. The secondary objective was to evaluate its pharmacokinetic properties. Results: RMC-035 was well tolerated. The nature and frequency of adverse events (AEs) were consistent with the expected background rates in the underlying patient population with no AEs reported as related to study drug. No clinically relevant changes were observed for vital signs or laboratory parameters except for renal biomarkers. Several established AKI urine biomarkers were reduced at 4 hours after first dose administration in the treatment group, indicating a reduced perioperative tubular cell injury following RMC-035 treatment. Conclusion: Multiple intravenous doses of RMC-035 were well tolerated in patients undergoing cardiac surgery. Observed RMC-035 plasma exposures were safe and in the range of expected pharmacological activity. Furthermore, urine biomarkers suggest reduced perioperative kidney cell injury, warranting further investigation of RMC-035 as a potential renoprotective treatment. |
| first_indexed | 2024-04-09T14:25:47Z |
| format | Article |
| id | doaj.art-1eccb46e54004c8dbe36bd84b9a77e23 |
| institution | Directory Open Access Journal |
| issn | 2468-0249 |
| language | English |
| last_indexed | 2024-04-09T14:25:47Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj.art-1eccb46e54004c8dbe36bd84b9a77e232023-05-04T04:12:54ZengElsevierKidney International Reports2468-02492023-05-0185980988Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and PharmacokineticsRaphael Weiss0Melanie Meersch1Carola Wempe2Thilo von Groote3Tobias Agervald4Alexander Zarbock5Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, GermanyDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, GermanyDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, GermanyDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, GermanyGuard Therapeutics International AB, Stockholm, Sweden; Renal Division, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, SwedenDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany; Correspondence: Alexander Zarbock, Department of Anesthesiology, Critical Care Medicine and Pain Therapy, University Hospital Münster, Albert-Schweitzer-Campus 1, Gebäude A1, Münster 48149, Germany.Introduction: Acute kidney injury (AKI) is a common complication in cardiac surgery patients and prevention is needed to improve clinical outcomes. Alpha-1-microglobulin (A1M) is a physiological antioxidant with strong tissue-protective and cell-protective properties that has demonstrated renoprotective effects. RMC-035, a recombinant variant of endogenous human A1M, is being developed for the prevention of AKI in cardiac surgery patients. Methods: In this phase 1b, randomized, double-blind, and parallel group clinical study, 12 cardiac surgery patients undergoing elective, open-chest, on-pump coronary artery bypass graft and/or valve surgery with additional predisposing AKI risk factors were enrolled to receive in total 5 intravenous doses of either RMC-035 or placebo. The primary objective was to evaluate the safety and tolerability of RMC-035. The secondary objective was to evaluate its pharmacokinetic properties. Results: RMC-035 was well tolerated. The nature and frequency of adverse events (AEs) were consistent with the expected background rates in the underlying patient population with no AEs reported as related to study drug. No clinically relevant changes were observed for vital signs or laboratory parameters except for renal biomarkers. Several established AKI urine biomarkers were reduced at 4 hours after first dose administration in the treatment group, indicating a reduced perioperative tubular cell injury following RMC-035 treatment. Conclusion: Multiple intravenous doses of RMC-035 were well tolerated in patients undergoing cardiac surgery. Observed RMC-035 plasma exposures were safe and in the range of expected pharmacological activity. Furthermore, urine biomarkers suggest reduced perioperative kidney cell injury, warranting further investigation of RMC-035 as a potential renoprotective treatment.http://www.sciencedirect.com/science/article/pii/S2468024923011683acute kidney injuryalpha-1-microglobulincardiac surgeryinflammationperioperative medicineprevention |
| spellingShingle | Raphael Weiss Melanie Meersch Carola Wempe Thilo von Groote Tobias Agervald Alexander Zarbock Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics Kidney International Reports acute kidney injury alpha-1-microglobulin cardiac surgery inflammation perioperative medicine prevention |
| title | Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics |
| title_full | Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics |
| title_fullStr | Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics |
| title_full_unstemmed | Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics |
| title_short | Recombinant Alpha-1-Microglobulin (RMC-035) to Prevent Acute Kidney Injury in Cardiac Surgery Patients: Phase 1b Evaluation of Safety and Pharmacokinetics |
| title_sort | recombinant alpha 1 microglobulin rmc 035 to prevent acute kidney injury in cardiac surgery patients phase 1b evaluation of safety and pharmacokinetics |
| topic | acute kidney injury alpha-1-microglobulin cardiac surgery inflammation perioperative medicine prevention |
| url | http://www.sciencedirect.com/science/article/pii/S2468024923011683 |
| work_keys_str_mv | AT raphaelweiss recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics AT melaniemeersch recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics AT carolawempe recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics AT thilovongroote recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics AT tobiasagervald recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics AT alexanderzarbock recombinantalpha1microglobulinrmc035topreventacutekidneyinjuryincardiacsurgerypatientsphase1bevaluationofsafetyandpharmacokinetics |